University awarded $12 million to further develop opioid use disorder drug
<p>Charles P. France, PhD, to lead methocinnamox drug development program The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was awarded a $12 million cooperative agreement (U01) from the National Institutes of Health’s National Institute on Drug Abuse to further develop methocinnamox (MCAM) as a treatment for opioid use disorder. […]</p>